119 related articles for article (PubMed ID: 25738879)
21. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis.
Childs LM; Paschalis EP; Xing L; Dougall WC; Anderson D; Boskey AL; Puzas JE; Rosier RN; O'Keefe RJ; Boyce BF; Schwarz EM
J Bone Miner Res; 2002 Feb; 17(2):192-9. PubMed ID: 11811549
[TBL] [Abstract][Full Text] [Related]
22. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the osteoclast activity with the application of recombinant murine RANK protein.
Tang P; Zhang L; Xu M; Zhang L; Wang Y
Artif Cells Blood Substit Immobil Biotechnol; 2010 Aug; 38(4):169-77. PubMed ID: 20367548
[TBL] [Abstract][Full Text] [Related]
24. Recombinant soluble receptor activator of nuclear factor-kappaB inhibits parathyroid hormone-induced osteoclastogenesis in vitro.
Wang BL; Liang H; Zheng F; Li XX; Liu YB; Dai CL
Sheng Li Xue Bao; 2007 Apr; 59(2):169-74. PubMed ID: 17437039
[TBL] [Abstract][Full Text] [Related]
25. Calycosin attenuates osteoporosis and regulates the expression of OPG/RANKL in ovariectomized rats
Li N; Tu Y; Shen Y; Qin Y; Lei C; Liu X
Pharmazie; 2016 Oct; 71(10):607-612. PubMed ID: 29441931
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of osteoclast bone resorption activity through osteoprotegerin-induced damage of the sealing zone.
Song R; Gu J; Liu X; Zhu J; Wang Q; Gao Q; Zhang J; Cheng L; Tong X; Qi X; Yuan Y; Liu Z
Int J Mol Med; 2014 Sep; 34(3):856-62. PubMed ID: 25017214
[TBL] [Abstract][Full Text] [Related]
27. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
Koyama H; Nakade O; Takada Y; Kaku T; Lau KH
J Bone Miner Res; 2002 Jul; 17(7):1219-29. PubMed ID: 12096835
[TBL] [Abstract][Full Text] [Related]
28. Osteoprotegerin-Knockout Mice Developed Early Onset Root Resorption.
Liu Y; Du H; Wang Y; Liu M; Deng S; Fan L; Zhang L; Sun Y; Zhang Q
J Endod; 2016 Oct; 42(10):1516-22. PubMed ID: 27663616
[TBL] [Abstract][Full Text] [Related]
29. Phloretin promotes osteoclast apoptosis in murine macrophages and inhibits estrogen deficiency-induced osteoporosis in mice.
Lee EJ; Kim JL; Kim YH; Kang MK; Gong JH; Kang YH
Phytomedicine; 2014 Sep; 21(10):1208-15. PubMed ID: 24932975
[TBL] [Abstract][Full Text] [Related]
30. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
31. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
Shalhoub V; Faust J; Boyle WJ; Dunstan CR; Kelley M; Kaufman S; Scully S; Van G; Lacey DL
J Cell Biochem; 1999 Feb; 72(2):251-61. PubMed ID: 10022507
[TBL] [Abstract][Full Text] [Related]
32. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
33. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.
Nakamura M; Udagawa N; Matsuura S; Mogi M; Nakamura H; Horiuchi H; Saito N; Hiraoka BY; Kobayashi Y; Takaoka K; Ozawa H; Miyazawa H; Takahashi N
Endocrinology; 2003 Dec; 144(12):5441-9. PubMed ID: 14500574
[TBL] [Abstract][Full Text] [Related]
34. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
35. Osteoprotegerin gene-modified BMSCs with hydroxyapatite scaffold for treating critical-sized mandibular defects in ovariectomized osteoporotic rats.
Liu X; Bao C; Xu HHK; Pan J; Hu J; Wang P; Luo E
Acta Biomater; 2016 Sep; 42():378-388. PubMed ID: 27318268
[TBL] [Abstract][Full Text] [Related]
36. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
[TBL] [Abstract][Full Text] [Related]
37. Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow.
Shibata T; Shira-Ishi A; Sato T; Masaki T; Masuda A; Hishiya A; Ishikura N; Higashi S; Uchida Y; Saito MO; Ito M; Ogata E; Watanabe K; Ikeda K
J Bone Miner Res; 2002 Apr; 17(4):622-9. PubMed ID: 11918219
[TBL] [Abstract][Full Text] [Related]
38. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
Kaji H; Kanatani M; Sugimoto T; Chihara K
Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
[TBL] [Abstract][Full Text] [Related]
39. The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.
Padagas J; Colloton M; Shalhoub V; Kostenuik P; Morony S; Munyakazi L; Guo M; Gianneschi D; Shatzen E; Geng Z; Tan HL; Dunstan C; Lacey D; Martin D
Calcif Tissue Int; 2006 Jan; 78(1):35-44. PubMed ID: 16362459
[TBL] [Abstract][Full Text] [Related]
40. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
Swanson C; Lorentzon M; Conaway HH; Lerner UH
Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
